Stop TB Partnership

Stop TB Partnership is a global network of partners committed to eliminating tuberculosis as a public health problem. It was established in 2001 and is hosted by the United Nations Office for Project Services in Geneva. The partnership brings together expertise from governments, non-governmental organizations, academic institutions, private sector companies, and communities affected by TB to drive innovation and accelerate progress against the disease. Its mission aligns with the World Health Organization's End TB Strategy and the health-related targets of the Sustainable Development Goals.

History

The origins of the partnership trace back to the 1998 G8 summit in Birmingham, where leaders recognized the growing threat of infectious diseases like tuberculosis. This led to a 2000 meeting in Amsterdam, resulting in the Amsterdam Declaration to Stop TB, which called for a new global partnership. Officially launched in 2001, it built upon the work of earlier initiatives coordinated by the World Health Organization. A pivotal moment was the 2006 adoption of the Global Plan to Stop TB, which outlined a comprehensive strategy for TB control. The partnership's mandate was further reinforced by the 2018 United Nations General Assembly High-Level Meeting on TB, which elevated political commitment to ending the epidemic.

Structure and governance

The partnership operates through a coordinating board that includes representatives from all constituent groups, ensuring a multi-stakeholder approach. The board provides strategic oversight, while the secretariat, based in Geneva and led by an Executive Director, manages day-to-day operations and implements the work plan. Key governance bodies include the Communities Delegation, which ensures the voices of those affected by TB are central to decision-making. The partnership also collaborates closely with major health and development institutions, including the World Health Organization, the Global Fund to Fight AIDS, Tuberculosis and Malaria, and the U.S. Agency for International Development.

Key initiatives and programs

A flagship initiative is the Global Drug Facility, which provides quality-assured TB drugs and diagnostics to countries at lower prices. The TB REACH initiative funds innovative projects to find missing people with TB and improve treatment access. The partnership also manages the Global Laboratory Initiative to strengthen diagnostic networks. Advocacy campaigns like World TB Day on March 24th raise global awareness. Furthermore, it supports the development of new tools through partnerships with entities like the Bill & Melinda Gates Foundation and the European and Developing Countries Clinical Trials Partnership, focusing on better vaccines, drugs, and diagnostics.

Funding and partnerships

Financial support comes from a diverse array of donors, including national governments like those of the United States, the United Kingdom, and Canada, as well as philanthropic organizations such as the Bill & Melinda Gates Foundation. Core funding is also provided through its hosting arrangement with the United Nations Office for Project Services. Strategic partnerships with technical agencies like the World Health Organization and financing mechanisms like the Global Fund to Fight AIDS, Tuberculosis and Malaria are crucial for resource mobilization and implementation. Collaboration with the private sector, including pharmaceutical companies like Johnson & Johnson, is essential for research and development and supply chain solutions.

Impact and achievements

The partnership has contributed to significant milestones in the global fight against tuberculosis. Its advocacy was instrumental in securing the political declaration from the 2018 United Nations General Assembly High-Level Meeting on TB. Through the Global Drug Facility, it has facilitated access to treatment for millions of patients in over 130 countries. Initiatives like TB REACH have successfully identified and treated millions of missing TB cases. The partnership's work has helped shape critical global policies and targets, including those within the World Health Organization's End TB Strategy. Despite progress, ongoing challenges such as drug-resistant TB and the impact of the COVID-19 pandemic underscore the continued need for its coordinated global efforts.

Category:Health organizations Category:Tuberculosis Category:Organizations established in 2001